Announcements Trials
Browse Landscape

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 17Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

Flow Cytometry 36Gene Expression Profiling 34Surveys and Questionnaires 27Polymerase Chain Reaction 24Microarray Analysis 23Blood Specimen Collection 19Interviews as Topic 18Imatinib Mesylate 15Amplified Fragment Length Polymorphism Analysis 14Reverse Transcriptase Polymerase Chain Reaction 13Cytogenetic Analysis 13Rituximab 12venetoclax 11nilotinib 10Psychiatric Rehabilitation 10Dasatinib 10Immunologic Techniques 9DNA Methylation 9Blotting, Western 9ponatinib 8Watchful Waiting 8Observation 8In Situ Hybridization, Fluorescence 8Base Sequence 8Azacitidine 8ibrutinib 7fludarabine 7bosutinib 7Therapeutics 7Specimen Handling 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × olverembatinib × Other hematologic neoplasm × Clear all
NCT07383298 2026-02-03

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Peking University People's Hospital

Enrolling by invitation
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06390306 2025-06-03

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Peking University People's Hospital

Recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡